Yes, a UK pharmaceutical company can act as an OBP for non-UK MAHs as long as Appendix 4 – Addendum only applicable to non-EEA OBPs from the Participation Agreement (PA) is signed.

*The date is subject to the relevant written guarantees from the UK being in place.